Company: ENTXW
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001178913-25-001674
Chunk: 44

Company: Entera Bio Ltd.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 3
Chunk 44
---
Not required for smaller reporting companies.

                    25

ITEM 4. CONTROLS AND PROCEDURES

                    Evaluation of Disclosure Controls and Procedures

                    Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2025, which we refer to as the Evaluation Date. Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION.

ITEM 1. LEGAL PROCEEDINGS

We are not currently a party to any material legal proceedings.

ITEM 1A. RISK FACTORS

                    There have been no material changes with respect to the risk factors disclosed in Part I, Item 1A. of our 2024 Annual Report.

                    26

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

                        During the quarter ended March 31, 2025, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement”, as defined in Item 408 of Regulation S-K.

                    27

ITEM 6. EXHIBITS

                          Exhibit No.

                          Description of Exhibits

                          10.1*

                          Collaboration and License Agreement, dated March 16, 2025, by and among Entera Bio Ltd., OPKO Health, Inc. and OPKO Biologics Ltd., filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on March 17, 2025, and incorporated herein by reference.

                          31.1